GW8510 / Ege University, GSK - LARVOL DELTA

GW8510 alleviates muscle atrophy and skeletal muscle dysfunction in mice through AMPK/PGC1α signaling. (PubMed, Int J Mol Med) - "Overall, GW8510 mitigated muscle atrophy via the activation of the AMPK/PGC1α pathway. GW8510 could serve as a novel therapeutic agent for the prevention of muscle atrophy."

Journal • Preclinical • Fatigue • Muscular Atrophy • FBXO32

Construction of the prognostic enhancer RNA regulatory network in osteosarcoma. (PubMed, Transl Oncol) - "We constructed an eRNA-based prognostic model for predicting the OS patients' prognosis and explored the potential regulation network for OS tumorigenesis by an integrated bioinformatics analysis, providing promising therapeutic targets for OS patients."

Journal • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Transplant Rejection • CD8 • CEBPA

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer. (PubMed, Front Oncol) - "More importantly, in vitro and in vivo studies confirmed that GW-8510 and other CDK inhibitors (Dinaciclib, and Palbociclib) can induce pyroptosis by activating caspase-3 and GSDME, which might be the mechanism for their immune regulation potentials. GW-8510, as well as other CDK inhibitors, might serve as potential immune regulators and pyroptosis promotors in TNBC."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CASP3 • GSDME

Expression and clinical significance of TIMELESS in glioma. (PubMed, Int J Clin Exp Pathol) - "We predict small molecules to inhibit TIMELESS such as 8-azaguanine, gw8510, 6-thioguanosine, and ursodeoxycholic acid. This study is the first comprehensive analysis of TIMELESS, revealing a relationship between this novel oncogene, clinical characteristics of patients with glioma, and a mechanism leading to poor prognosis. It also provides a biomarker for diagnosis and treatment of glioma and reveal the pathologic progress of glioma at the genetic level."

Clinical • Journal • Brain Cancer • Glioma • Oncology • Solid Tumor • TIMELESS

The use of a Gene Expression Signature and Connectivity Map to repurpose drugs for Bipolar Disorder. (PubMed, World J Biol Psychiatry) - "This study shows that GES and CMap can be used as tools to repurpose drugs for BD."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders

Identification of hub genes and compounds controlling ovarian cancer stem cell characteristics via stemness indices analysis. (PubMed, Ann Transl Med) - "Of these, 11 compounds, including MS-275, DL-thiorphan, and GW-8510, which have never been studied in OC stem cells, were screened as underlying treatments targeting OC stem cells. Altogether, 72 hub genes that were closely linked to OC stem cell characteristics were found to mainly participate in cell division and proliferation. Moreover, compounds that disturb these hub gens were identified and can be considered underlying targets for inhibiting OC stem cells."

Cancer stem cells • Journal • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor